论文部分内容阅读
Zeneca公司已经把胸苷酸合成酶（TS）抑制剂raltitrexed（商品名Tomudex）首次在英国投放市场，作为晚期结肠、直肠癌的一线姑息治疗药物。Tomudex将是35年来一线治疗结肠、直肠癌的第一个新的细胞毒药物。Zeneca估计这类抗代谢药全世界的销售额在8亿英镑以上。该产品在卢森堡
Zeneca Corporation has put the thymidylate synthase (TS) inhibitor raltitrexed (trade name Tomudex) on the market for the first time in the UK as a palliative drug for advanced colon, rectal cancer. Tomudex will be the first new cytotoxic drug to treat colorectal cancer in 35 years. Zeneca estimates that such anti-metabolites worldwide have sales of more than 800 million pounds. This product is in Luxembourg